All GLG News Analyses Filed Under: Ophthalmology

Silicone Hydrgol lenses are the latest technology in the contact lens industry.  Nearly 100% of of my new fits are silicone hydrogel lenses, and the 2 week modality is the most popular wearing schedule. Currenly J&J has the lion's share of the market with their Acuvue Advance and Oasys contact...

I’m not so sure that this is a leap forward for CooperVision.  After long delays for the release of the Biofinity lens, a two-week version has just been released.  The material properties are reportedly “nice”, but certainly scaled back from what was reportedly achieved with Comfilcon...

Any new efficacious glaucoma treatment is welcome and needed, but patient compliance remains a factor.  A single injection treatment that provides IOP reduction for 3 months would greatly improve success in IOP control.  I would, however, like to see a lower target pressure set for the...

A new model of the increasing popular Ex-Press Shunt is quite effective in an early study.  Its is quite safe and effective; and simpler substitute for trabeculectomy.  It could be the first line  in the surgical management of glaucoma.

Alcon (ACL) reported positive interim results for their injectable medication for glaucoma.  A single injection of anecortave acetate  resulted in control of IOP at the three month follow up.  This could be a promising medication for IOP control in glaucoma.

Alcon becomes part of a larger group that is very interested in profiting from eye care. The patient will probably not see any changes in labeling or distribution for a few years. The companies interlock well, but do not have a lot of overlap.....except for sales reps!

The light adjustable lens is a lens implant that is placed in the eye like a tradition intraocular lens during cataract surgery.  The unique difference is that it can be treated with a special light after surgical implant (weeks to months later) to correct any residual refractive errors or to fine...

1. AMD 2. Anti VEG 3. Visudyne

In many respects, it is good that this trial was done.  For many years, retinal physicians had used Avastin injections preferentially over Lucentis for the treatment of AMD because of the vast difference in cost.

I agree...the present situation is really quite absurd...in most practices...IF a third party is willing to pay for Lucentis...patients usually get Lucentis...if patients have to pay themselves...they usually receive Avastin...despite there not being a shred of convincing evidence that Lucentis is superior...